Seattle-based Omeros Corporation (OMER) is a commercial-stage biopharmaceutical company whose lead product, YARTEMLEA (narsoplimab), became the first FDA-approved therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy in December 2025, alongside a pipeline targeting complement-mediated disease and cancers. Shares closed Monday at $16.68 and were trading at $13.37 on Tuesday, a decline of 19.84%, or $3.31 per share. The direction was decisively lower. The immediate cause cited by markets was the company's third-quarter report: revenue landed short of expectations, sequential growth decelerated sharply, and management again declined to provide revenue guidance.
YARTEMLEA gross revenue reached $41.8 million, up 29.6% from $32.2 million in the second quarter, with net product sales rising 26% to $35.9 million. That was still below consensus near $37.3 million. The more consequential signal for investors was the shape of the curve: sequential net sales growth decelerated from 188% in the second quarter to 26% in the third, even as ordering accounts climbed to 109 from 73.
Adjusted EPS of $0.06 beat estimates, operating income turned positive at $4.5 million and operating cash flow reached $13.3 million — the second consecutive positive quarter, ahead of the company's original 2027 target. The market, however, traded the top line rather than the margin line, a pattern consistent with a launch story that had already been priced for acceleration.
Gross-to-net deductions rose to 14.0% from 11.5%, driven by heavier purchasing from 340B-covered entities, and management indicated the figure could drift into the high teens. That mix shift supports broader hospital access but means reported net revenue will lag gross demand growth, and consensus models appear to have underestimated the drag. The revenue shortfall was modest in isolation; its implication for future net pricing was not.
The GAAP picture was stark: a net loss of $57.4 million, or $0.79 per share, versus net income of $13.2 million in the prior quarter. The swing was almost entirely a $62.0 million non-cash mark-to-market loss on a derivative tied to the 2029 convertible notes — a charge that rises with the share price and reverses with it. Management's decision to withhold revenue guidance, citing limited visibility into patient-level data and launch dynamics, removed a supporting pillar for valuation. The OMS527 cocaine-use-disorder trial's enrollment slipped to early 2027, and the October CHMP decision closing the European pathway remains a structural overhang.
Volume was heavy from the opening bell, with more than 240,000 shares trading in the first five minutes against a daily average near 750,000. The stock opened at $14.59 and touched $12.71 before stabilizing near $13.40. The move broke decisively below the October lows around $15.85 and left shares at their weakest level since mid-August, far under their 50- and 200-day moving averages. Biotech exchange-traded funds traded flat to slightly higher while the S&P 500 and Russell 2000 eased, underscoring the absence of sector or macro participation. Market capitalization sits near $1 billion, with short interest above 12 million shares, a positioning backdrop that can magnify single-session gaps.
The scale runs from 0, meaning no meaningful news and an ordinary move for the stock, to 100, meaning transformative news and an extreme, rare price move. Omeros scores 64 out of 100.
The verified news — a revenue miss, decelerating sequential growth, widening discounts and withheld guidance — was material but not transformational relative to the company's size. The price response was far more dramatic than the catalyst: the 19.84% decline was roughly seven times the stock's average absolute daily move of 2.82% over the past 60 sessions, and no session in that window produced a comparable drop. Moderate news plus an extreme, rare move combine into the mid-60s.
Attention turns to fourth-quarter YARTEMLEA demand, the first full quarter reflecting Medicare's new technology add-on payment, which took effect October 1 and can add up to $287,079 per eligible inpatient case. Management said growth carried into the fourth quarter but offered no figures, and expects to begin formal guidance at some point in 2027. Investors will watch gross-to-net trends, cash of $95.3 million after the convertible repurchase, and the remaining $40.3 million of 2029 notes. Up to $100 million in near-term Novo Nordisk milestones tied to zaltenibart offers a potential liquidity offset, and a December industry hematology meeting provides a venue for commercial updates. Analysts remain Buy-rated on balance, though estimate revisions are likely. Principal risks are further launch deceleration, sustained discount pressure, and financing needs if cash inflows slow.
Tickeron operates hundreds of AI trading bots spanning thousands of tickers, but the Trending AI Robots page curates only those posting the strongest performance under current market conditions. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market regimes change. Reviewing this section can help traders see which automated strategies are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for OMER moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 28 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OMER as a result. In 69 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for OMER turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.586). P/E Ratio (8.812) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceutical products
Industry Biotechnology